Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture

Vaccine

Volumn 16, Issue 13, 1998, Pages 1331-1335

  Halperin, Scott A ^a   Christine Nestruck, A ^b   Eastwood, Brian J ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b BioChem Vaccines   (Canada)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cell culture; Influenza; Influenza vaccine

Indexed keywords

INFLUENZA VACCINE;

ADULT; ANIMAL CELL; ARTICLE; CELL STRAIN; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; LICENCE; MALE; MAMMAL CELL; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINE PRODUCTION; VIRION; VIRUS TITRATION;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; CHICK EMBRYO; CLONE CELLS; DOGS; DOUBLE-BLIND METHOD; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED;

EID: 0032145014     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00011-5     Document Type: Article

References (16)

1. 1 Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly Rep. 1996, 45(RR-5), 1-19.
2. 2 < collabNational Advisory Committee on Immunization Statement on influenza vaccination for the 1996-97 season. Can. Commun. Dis. Rep. 1996, 22, 89-97.
3. 3 Webster, R.G., Laver, W.G. and Air, G.M. Antigenic variation among type A influenza viruses. In: Genetics of Influenza Viruses (Eds Palese P. and Kinepbury D.W.). Springer-Verlag, New York, 1983, p. 127.
4. 4 Robertson, J.S. Clinical influenza virus and the embryonated hen's egg. Rev. Med. Virol. 1993, 3, 97-106.
5. 5 Coller, H.A. and Coller, B.S. Poisson statistical analysis of repetitive subcloning by the limiting dilution technique as a way of assessing hybridoma monoclonality. Meth. Enzymol. 1986, 121, 412-417.
6. 6 Center for Biologics Evaluation and Research. Food and Drug Administration. Points to consider in the characterization of cell lines used to produce biologicals. Office of the Federal Register National Archives and Records Administration. FDA 21CFR 610.18, US Government Printing Office, Washington DC, 1987.
7. 7 WHO Expert Committee on Biological Standardization 1996. Final draft requirements for use of animal cells as in vitro substrates for the production of biologicals. World Health Organization Technical Report Series Requirements for Biological Substances. World Health Organization, Geneva, 1995, Vol. 50, pp. 1-40 (final draft issued 17 January 1997).
8. 8 Drugs Directorate. Health and Welfare Canada. Guidelines: Utilization of Continuous Cell Lines in the Manufacture of Biologics. Supply and Services Canada, Ottawa, Canada, 1990.
9. 9 Sanger, F., Nicler, S. and Coulson, A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 5463-5467.
10. 10 Dowdle, W.A., Kendal, A.P. and Noble, G.R. In: Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections (Eds Lennette E.H. and Schmidt N.J.). American Public Health Association, Washington, DC, 1979, pp. 585-609.
11. 11 Commission of the European Community. Rules Governing Medicinal Products in the European Community. Harmonisation of Requirements for Influenza Vaccines. European Community Publications Office, Luxembourg, 1992, pp. 93-98.
12. 12 Palache, A.M., Brands, R. and van Scharrenburg, G.J.M. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 1997, 176, (Suppl. 1), S20-S23.
13. 13 Rocha, E.P., Xu, X., Hall, H.E., Allen, J.R., Regnery, H.L. and Cox, N.J. Comparison of 10 influenza A (H1N1 and H3N2) heamagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J. Gen. Virol. 1993, 74, 2513-2518.
14. 14 Kodihalli, S., Justewicz, D.M., Gubareva, L.V. and Webster, R.G. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J. Virol. 1995, 69, 4888-4897.
15. 15 Katz, J.M. and Webster, R.G. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 1989, 160, 191-198.
16. 16 Wood, J.M., Oxford, J.S., Dunleavy, U., Newman, R.W., Major, D. and Robertson, U.S. Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule. Virology 1989, 171, 214-221.